Cargando…
Antibody Responses after SARS-CoV-2 Vaccination in Patients with Liver Diseases
The novel mRNA-based vaccines against SARS-CoV-2 display encouraging safety and efficacy profiles. However, there is a paucity of data regarding their immunogenicity and safety in patients with liver diseases (PWLD), especially in those with cirrhosis. We prospectively assessed anti-SARS-CoV-2 S-spi...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8876976/ https://www.ncbi.nlm.nih.gov/pubmed/35215801 http://dx.doi.org/10.3390/v14020207 |
_version_ | 1784658297160204288 |
---|---|
author | Bakasis, Athanasios-Dimitrios Bitzogli, Kleopatra Mouziouras, Dimitrios Pouliakis, Abraham Roumpoutsou, Maria Goules, Andreas V. Androutsakos, Theodoros |
author_facet | Bakasis, Athanasios-Dimitrios Bitzogli, Kleopatra Mouziouras, Dimitrios Pouliakis, Abraham Roumpoutsou, Maria Goules, Andreas V. Androutsakos, Theodoros |
author_sort | Bakasis, Athanasios-Dimitrios |
collection | PubMed |
description | The novel mRNA-based vaccines against SARS-CoV-2 display encouraging safety and efficacy profiles. However, there is a paucity of data regarding their immunogenicity and safety in patients with liver diseases (PWLD), especially in those with cirrhosis. We prospectively assessed anti-SARS-CoV-2 S-spike IgG antibodies and neutralizing activity in fully vaccinated PWLD (n = 87) and controls (n = 40). Seroconversion rates were 97.4% (37/38) in cirrhotic PWLD, 87.8% (43/49) in non-cirrhotic PWLD and 100% (40/40) in controls. Adequate neutralizing activity was detected in 92.1% (35/38), 87.8% (43/49) and 100% (40/40) of cirrhotics, non-cirrhotics and controls, respectively. On multivariable analysis, immunosuppressive treatment was negatively correlated with anti-SARS-CoV-2 antibody titers (coefficient (SE): −2.716 (0.634), p < 0.001) and neutralizing activity (coefficient (SE): −24.379 (4.582), p < 0.001), while age was negatively correlated only with neutralizing activity (coefficient (SE): −0.31(0.14), p = 0.028). A total of 52 responder PWLD were reassessed approximately 3 months post-vaccination and no differences were detected in humoral responses between cirrhotic and non-cirrhotic PWLD. No significant side effects were noted post vaccination, while no symptomatic breakthrough infections were reported during a 6-month follow up. Overall, our study shows that m-RNA-based SARS-CoV-2 vaccines are safe and efficacious in PWLD. However, PWLD under immunosuppressive treatment and those of advanced age should probably be more closely monitored after vaccination. |
format | Online Article Text |
id | pubmed-8876976 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-88769762022-02-26 Antibody Responses after SARS-CoV-2 Vaccination in Patients with Liver Diseases Bakasis, Athanasios-Dimitrios Bitzogli, Kleopatra Mouziouras, Dimitrios Pouliakis, Abraham Roumpoutsou, Maria Goules, Andreas V. Androutsakos, Theodoros Viruses Brief Report The novel mRNA-based vaccines against SARS-CoV-2 display encouraging safety and efficacy profiles. However, there is a paucity of data regarding their immunogenicity and safety in patients with liver diseases (PWLD), especially in those with cirrhosis. We prospectively assessed anti-SARS-CoV-2 S-spike IgG antibodies and neutralizing activity in fully vaccinated PWLD (n = 87) and controls (n = 40). Seroconversion rates were 97.4% (37/38) in cirrhotic PWLD, 87.8% (43/49) in non-cirrhotic PWLD and 100% (40/40) in controls. Adequate neutralizing activity was detected in 92.1% (35/38), 87.8% (43/49) and 100% (40/40) of cirrhotics, non-cirrhotics and controls, respectively. On multivariable analysis, immunosuppressive treatment was negatively correlated with anti-SARS-CoV-2 antibody titers (coefficient (SE): −2.716 (0.634), p < 0.001) and neutralizing activity (coefficient (SE): −24.379 (4.582), p < 0.001), while age was negatively correlated only with neutralizing activity (coefficient (SE): −0.31(0.14), p = 0.028). A total of 52 responder PWLD were reassessed approximately 3 months post-vaccination and no differences were detected in humoral responses between cirrhotic and non-cirrhotic PWLD. No significant side effects were noted post vaccination, while no symptomatic breakthrough infections were reported during a 6-month follow up. Overall, our study shows that m-RNA-based SARS-CoV-2 vaccines are safe and efficacious in PWLD. However, PWLD under immunosuppressive treatment and those of advanced age should probably be more closely monitored after vaccination. MDPI 2022-01-21 /pmc/articles/PMC8876976/ /pubmed/35215801 http://dx.doi.org/10.3390/v14020207 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Brief Report Bakasis, Athanasios-Dimitrios Bitzogli, Kleopatra Mouziouras, Dimitrios Pouliakis, Abraham Roumpoutsou, Maria Goules, Andreas V. Androutsakos, Theodoros Antibody Responses after SARS-CoV-2 Vaccination in Patients with Liver Diseases |
title | Antibody Responses after SARS-CoV-2 Vaccination in Patients with Liver Diseases |
title_full | Antibody Responses after SARS-CoV-2 Vaccination in Patients with Liver Diseases |
title_fullStr | Antibody Responses after SARS-CoV-2 Vaccination in Patients with Liver Diseases |
title_full_unstemmed | Antibody Responses after SARS-CoV-2 Vaccination in Patients with Liver Diseases |
title_short | Antibody Responses after SARS-CoV-2 Vaccination in Patients with Liver Diseases |
title_sort | antibody responses after sars-cov-2 vaccination in patients with liver diseases |
topic | Brief Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8876976/ https://www.ncbi.nlm.nih.gov/pubmed/35215801 http://dx.doi.org/10.3390/v14020207 |
work_keys_str_mv | AT bakasisathanasiosdimitrios antibodyresponsesaftersarscov2vaccinationinpatientswithliverdiseases AT bitzoglikleopatra antibodyresponsesaftersarscov2vaccinationinpatientswithliverdiseases AT mouziourasdimitrios antibodyresponsesaftersarscov2vaccinationinpatientswithliverdiseases AT pouliakisabraham antibodyresponsesaftersarscov2vaccinationinpatientswithliverdiseases AT roumpoutsoumaria antibodyresponsesaftersarscov2vaccinationinpatientswithliverdiseases AT goulesandreasv antibodyresponsesaftersarscov2vaccinationinpatientswithliverdiseases AT androutsakostheodoros antibodyresponsesaftersarscov2vaccinationinpatientswithliverdiseases |